These findings are important in that STEMI patients are especially at higher risk of bleeding compared to other acute coronary syndrome, and that vast majority of AMI patients are treated with potent P2Y12 inhibitor in current clinical practice [5,6,7,23,24]. This evidence concerns the gene P2RY12 and acute coronary syndrome.